Ovarian Cancer

News

Guadecitabine Yields Modest Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer

07/23/2020

Guadecitabine as a primer for pembrolizumab has modest anti-tumor activity in patients with advanced, platinum-resistant, recurrent ovarian cancer.

Guadecitabine as a primer for...

07/23/2020

Oncology

News

Investigator-Assessed PFS Reliable Alternative to BICR in Ovarian Cancer Clinical Trials

06/24/2020

Researchers in the VELIA clinical trial suggest that investigator-assessed PFS in ovarian cancer trials is a reliable alternative to assessment via blinded independent central review (BICR).

Researchers in the VELIA...

06/24/2020

Oncology

News

Hydroxychloroquine Plus Itraconazole Shows No Antitumor Activity in Advanced EOC

06/22/2020

Although hydroxychloroquine plus itraconazole was feasible in heavily pre-treated patients with platinum-resistant EOC, the regimen did not demonstrate antitumor activity.

Although hydroxychloroquine plus...

06/22/2020

Oncology

Adding Nintedanib to Neoadjuvant Chemo Reduces Therapy Efficacy in Ovarian Cancer

06/03/2019

Adding nintedanib to neoadjuvant chemo increases toxicity and compromises chemotherapy efficacy in patients with advanced epithelial ovarian cancer, according to data presented at ASCO 2019.

Adding nintedanib to neoadjuvant...

06/03/2019

Oncology

Response to Immune Checkpoint Inhibitors Not Tied to BRCA 1/2 Mutations in Ovarian Cancer

05/31/2019

Results from a study presented at ASCO 2019 show that in heavily pretreated patients with ovarian cancer being given immune checkpoint inhibitors, BRCA 1/2 mutations were not related to improved response or survival.

Results from a study presented...

05/31/2019

Oncology

Combination Therapy Improves PFS in Women With Platinum-Sensitive Ovarian Cancer

05/30/2019

Combination therapy significantly improved PFS in women with platinum-sensitive recurrent ovarian cancer, according to data being presented at ASCO 2019.

Combination therapy...

05/30/2019

Oncology

Carboplatin Significantly Less Active Than Carboplatin–Paclitaxel in Elderly Patients With Ovarian Cancer

05/29/2019

Carboplatin monotherapy significantly worsened survival in vulnerable, elderly patients with ovarian cancer, according to a study being presented at ASCO 2019.

Carboplatin monotherapy...

05/29/2019

Oncology